Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 6
Submit an article Journal homepage
285
Views
9
CrossRef citations to date
0
Altmetric
Drug Profile

Cost–effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections

Mark Bounthavong Veterans Affairs, San Diego Healthcare System, UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, 3350 La Jolla Village Drive (119), San Diego, CA 92161, USA. [email protected]; Veterans Affairs, San Diego Healthcare System, UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, 3350 La Jolla Village Drive (119), San Diego, CA 92161, USA. [email protected]
&
Donald I Hsu Western University of Health Sciences, College of Pharmacy, 309 Second Street, Pomona, CA 91766, USA; Department of Infectious Diseases, St. Joseph Hospital, 1100 W. Stewart Drive, Orange, CA 92868, USA; Western University of Health Sciences, College of Pharmacy, 309 Second Street, Pomona, CA 91766, USA; Department of Infectious Diseases, St. Joseph Hospital, 1100 W. Stewart Drive, Orange, CA 92868, USA
Pages 683-698 | Published online: 09 Jan 2014

References

  • Shorr AF. Epidemiology and economic impact of methicillin-resistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics 25(9), 751–768 (2007).
  • Chambers HF. Community-associated MRSA – resistance and virulence converge. N. Engl. J. Med. 352(14), 1485–1487 (2005).
  • Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 357(4), 380–390 (2007).
  • Fridkin SK, Hageman JC, Morrison M et al.; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352(14), 1436–1444 (2005).
  • Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann. Intern. Med. 144(5), 368–370 (2006).
  • Moran GJ, Krishnadasan A, Gorwitz RJ et al.; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666–674 (2006).
  • Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166(19), 2138–2144 (2006).
  • Hsu DI, Hidayat LK, Quist R et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32(5), 378–385 (2008).
  • Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52(9), 3315–3320 (2008).
  • Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int. J. Antimicrob. Agents 16(Suppl. 1), S31–S34 (2000).
  • Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38(12), 1700–1705 (2004).
  • Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America and the Society of Infectious Diseases Pharmacists. Am. J. Health. Syst. Pharm. 66(1), 82–98 (2009).
  • Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52(4), 1330–1336 (2008).
  • Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration–time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49(4), 507–514 (2009).
  • Itani KM, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. 199(6), 804–816 (2010).
  • Kohno S, Yamaguchi K, Aikawa N et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J. Antimicrob. Chemother. 60(6), 1361–1369 (2007).
  • Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. 189(4), 425–428 (2005).
  • Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34(11), 1481–1490 (2002).
  • Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C; Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 49(6), 2260–2266 (2005).
  • Spellberg B. Skin and soft-tissue infections: modern evolution of an ancient problem. Clin. Infect. Dis. 51(8), 904–906 (2010).
  • Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin. Infect. Dis. 51(8), 895–903 (2010).
  • Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr. Med. Res. Opin. 26(2), 407–421 (2010).
  • Bounthavong M, Hsu DI, Okamoto MP. Cost–effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int. J. Clin. Pract. 63(3), 376–386 (2009).
  • Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost–effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health 14(5), 631–639 (2011).
  • Logman JF, Stephens J, Heeg B et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr. Med. Res. Opin. 26(7), 1565–1578 (2010).
  • Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch. Intern. Med. 168(14), 1585–1591 (2008).
  • Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann. Emerg. Med. 51(3), 291–298 (2008).
  • Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36(5), 592–598 (2003).
  • Kanerva M, Blom M, Tuominen U et al. Costs of an outbreak of methicillin-resistant Staphylococcus aureus. J. Hosp. Infect. 66(1), 22–28 (2007).
  • Marton JP, Jackel JL, Carson RT, Rothermel CD, Friedman M, Menzin J. Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims. Curr. Med. Res. Opin. 24(10), 2821–2828 (2008).
  • Menzin J, Marton JP, Meyers JL, Carson RT, Rothermel CD, Friedman M. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am. J. Infect. Control 38(1), 44–49 (2010).
  • McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin. Ther. 29(3), 469–477 (2007).
  • McKinnon PS, Sorensen SV, Liu LZ, Itani KM. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann. Pharmacother. 40(6), 1017–1023 (2006).
  • Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect. Control Hosp. Epidemiol. 22(2), 99–104 (2001).
  • Plowman R, Graves N, Griffin MA et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. J. Hosp. Infect. 47(3), 198–209 (2001).
  • Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J. Antimicrob. Chemother. 51(Suppl. 2), ii 37–ii44 (2003).
  • Plosker GL, Figgitt DP. Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections. Pharmacoeconomics 23(9), 945–964 (2005).
  • Grau S, Rubio-Terrés C. Pharmacoeconomics of linezolid. Expert Opin. Pharmacother. 9(6), 987–1000 (2008).
  • Milkovich G. Future pharmacoeconomic criteria for the treatment of infections. Int. J. Antimicrob. Agents 34(Suppl. 1), S12–S14 (2009).
  • De Cock E, Sorensen S, Levrat F et al. Cost–effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France. Med. Mal. Infect. 39(5), 330–340 (2009).
  • McKinnon PS, Carter CT, Girase PG, Liu LZ, Carmeli Y. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag. Care Interface 20(1), 23–34 (2007).
  • Schürmann D, Sorensen SV, De Cock E, Duttagupta S, Resch A. Cost–effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur. J. Health Econ. 10(1), 65–79 (2009).
  • Vinken A, Li Z, Balan D, Rittenhouse B, Wilike R, Nathwani D. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. J. Hosp. Infect. 49(Suppl. A), S13–S24 (2001).
  • Soria-Cedillo IF, Baca-Muro VI, Martinez-Revelles M, Jirash J, De la Mora-Chavez T, Garcia-Contreras F. A pharmacoeconomic approach of the use of intravenous antibiotic therapy for complicated skin and skin-structure infections in public health care institutions in Mexico. Value Health 12(3), A75–A76 (2009).
  • Briones B, Martinez Revelles M, Garcia-Contreras F. A cost–effectiveness analysis on the use of daptomycin for the treatment of skin and soft tissue infections with failure to vancomycin therapy in Mexico. Value Health 14(3), A118–A119 (2011).
  • Fujii RK, Takemoto MLS, Mould JF et al. Linezolid versus vancomycin for skin and soft tissue infections by methicilin-resistant Staphylococcus aureus: a cost comparison analysis under the private payer perspective in Brazil. Value Health 14(7), A270 (2011).
  • Fujii RK, Takemoto MLS, Mould JF et al. Linezolid versus vancomycin for skin and soft tissue infections by methicilin-resistant Staphylococcus aureus: a cost comparison analysis under the public hospital perspective in Brazil. Value Health 14(7), A272 (2011).
  • Stephens JM, Gao X, Verheggen BG, Shelbaya A, Haider S. Modeling the inpatient and outpatient costs of methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infections (CSSTI): a comparison of linezolid, vancomycin, daptomycin, and tigecycline. Value Health 12(3), A111 (2009).
  • Briggs AH. A Bayesian approach to stochastic cost–effectiveness analysis. Health Econ. 8(3), 257–261 (1999).
  • Fenwick E, O’Brien BJ, Briggs A. Cost–effectiveness acceptability curves – facts, fallacies and frequently asked questions. Health Econ. 13(5), 405–415 (2004).
  • United States. Public Health Service. Panel on cost–effectiveness in health and medicine, United States. Office of disease prevention and health promotion. In: Cost–effectiveness In Health and Medicine: Report To the U.S. Public Health Service, By the Panel on Cost–Effectiveness in Health and Medicine. OUP USA, NY, USA (1996).
  • Rosner AJ, Becker DL, Wong AH, Miller E, Conly JM. The costs and consequences of methicillin-resistant Staphylococcus aureus infection treatments in Canada. Can. J. Infect. Dis. Med. Microbiol. 15(4), 213–220 (2004).
  • Abrams K, Sansó B. Approximate Bayesian inference for random effects meta-analysis. Stat. Med. 17(2), 201–218 (1998).
  • Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Methods in health service research. An introduction to Bayesian methods in health technology assessment. BMJ 319(7208), 508–512 (1999).
  • Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol. Assess. 4(38), 1–130 (2000).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.